Aesica Pharmaceuticals and CMIC Holdings Co., a Japan-based CDMO with sites in the U.S., have signed an agreement for the mutual development of sales and marketing opportunities for respective clients in Europe and Japan. Both companies will work together to develop commercial opportunities for the U.S. market. This initiative will form the basis of a supply and quality agreement.
 
Aesica will seek expansion of business opportunities in Japan and the U.S., collaborating with CMIC customers who may require consultation and manufacturing in Europe. CMIC is looking to expand global commercial business opportunities outside of Japan, collaborating with Aesica customers who may require consultation or manufacturing in Japan. Additionally, both parties will pursue joint collaborative development of the U.S. market.
 
Dr. Robert Hardy, chief executive officer of Aesica, said, “This agreement will provide a tremendous opportunity to develop business and commercial opportunities for our customers in the Japanese market and in the U.S., whilst providing solid scope for us to expand our market share in these regions. We look forward to forging an extremely close working relationship and partnership between our two companies.”
 
Kazuo Nakamura, chairman and chief executive officer of CMIC, said, “There are tremendous synergies between CMIC and Aesica which will be exploited to the full commercial benefit of customers of each company. Whilst CMIC is a leading Japanese, full-service contract development and manufacturer of formulated products for the pharmaceutical industry, with established manufacturing sites in Japan, Korea and the U.S., Aesica is an international CDMO operating in the UK, Germany and Italy across both API and formulated products. The combined, European, Japanese and U.S. commercial expertise and presence is enormous.”